Enzo Biochem (ENZ) Reports Q2 EPS of $0.09, CEO to Step Down
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
March 15, 2021 4:05 PM EDTTotal second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemicSecond quarter clinical laboratory revenue of $24.0 million increased 92% on significant volume and pricing growth due to improved product mix Consolidated quarterly gross margin of 50% improved 2000 basis points year-over-yearAchieved adjusted EBITDA at $4.3 million for the quarter with increases in sequential and YOY profitabilityEPS of $0.05 for the quarter vs. EPS loss of ($0.16) in Q2 2020Dr. Elazar Rabbani, Founder and CEO, to step down as CEO and transition... More
